Literature DB >> 33364939

Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Jinfeng Shi1, Jiaxin Li1, Ziyi Xu1, Liang Chen1, Ruifeng Luo1, Chen Zhang1, Fei Gao1, Jinming Zhang1, Chaomei Fu1.   

Abstract

Celastrol, a natural bioactive ingredient derived from Tripterygium wilfordii Hook F, exhibits significant broad-spectrum anticancer activities for the treatment of a variety of cancers including liver cancer, breast cancer, prostate tumor, multiple myeloma, glioma, etc. However, the poor water stability, low bioavailability, narrow therapeutic window, and undesired side effects greatly limit its clinical application. To address this issue, some strategies were employed to improve the anticancer efficacy and reduce the side-effects of celastrol. The present review comprehensively focuses on the various challenges associated with the anticancer efficiency and drug delivery of celastrol, and the useful approaches including combination therapy, structural derivatives and nano/micro-systems development. The specific advantages for the use of celastrol mediated by these strategies are presented. Moreover, the challenges and future research directions are also discussed. Based on this review, it would provide a reference to develop a natural anticancer compound for cancer treatment.
Copyright © 2020 Shi, Li, Xu, Chen, Luo, Zhang, Gao, Zhang and Fu.

Entities:  

Keywords:  analogs of celastrol; anticancer activity; celastrol; combination therapy; nano/micro-formulation

Year:  2020        PMID: 33364939      PMCID: PMC7751759          DOI: 10.3389/fphar.2020.558741

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  176 in total

1.  Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.

Authors:  Sridhar Sreeramulu; Santosh Lakshmi Gande; Michael Göbel; Harald Schwalbe
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 2.  Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

3.  Celastrol inhibits migration, proliferation and transforming growth factor-β2-induced epithelial-mesenchymal transition in lens epithelial cells.

Authors:  Li-Ping Wang; Bao-Xin Chen; Yan Sun; Jie-Ping Chen; Shan Huang; Yi-Zhi Liu
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

Review 4.  Biosorption and biotransformation of hexavalent chromium [Cr(VI)]: A comprehensive review.

Authors:  Renitta Jobby; Pamela Jha; Anoop Kumar Yadav; Nitin Desai
Journal:  Chemosphere       Date:  2018-05-09       Impact factor: 7.086

5.  Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α.

Authors:  Soon Young Jang; Sung-Wuk Jang; Jesang Ko
Journal:  Cancer Lett       Date:  2010-10-12       Impact factor: 8.679

Review 6.  Treatment of Neurodegenerative Diseases with Bioactive Components of Tripterygium wilfordii.

Authors:  Jianheng Li; Jijun Hao
Journal:  Am J Chin Med       Date:  2019-05-15       Impact factor: 4.667

7.  [In vitro inhibition of celastrol on spermatozoa fertilization ability of guinea pig].

Authors:  Y Y Yuan; Z P Gu; Q X Shi; G W Qin; R S Xu; L Cao
Journal:  Yao Xue Xue Bao       Date:  1995

Review 8.  Lessons learned from lung and liver in-vivo gene therapy: implications for the future.

Authors:  Joost van Haasteren; Stephen C Hyde; Deborah R Gill
Journal:  Expert Opin Biol Ther       Date:  2018-08-10       Impact factor: 4.388

9.  Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma.

Authors:  Xi Cao; Ying Hu; Shi Luo; Yuejing Wang; Tao Gong; Xun Sun; Yao Fu; Zhirong Zhang
Journal:  Acta Pharm Sin B       Date:  2018-12-26       Impact factor: 11.413

Review 10.  Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors:  Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

View more
  24 in total

1.  Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin.

Authors:  Na Hui Kim; Minji Kwon; Jiwoo Jung; Hyo Byeong Chae; Jiwoo Lee; Yeo-Jun Yoon; In Seok Moon; Ho K Lee; Wan Namkung; Konstantina M Stankovic; Se A Lee; Jong Dae Lee; Sin-Aye Park
Journal:  Acta Pharmacol Sin       Date:  2022-04-27       Impact factor: 6.150

2.  Celastrol inhibits laser-induced choroidal neovascularization by decreasing VEGF induced proliferation and migration.

Authors:  Zhen Li; Ke-Wen Zhou; Fang Chen; Fu Shang; Ming-Xing Wu
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

3.  Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.

Authors:  Qilong Tan; Ziqun Liu; Xiaobo Gao; Yibo Wang; Xuefeng Qiu; Jiahui Chen; Liuchun Liang; Hongqian Guo; Shengsong Huang; Denglong Wu; Bing Zhou; Ronggui Hu; Zhenfei Li
Journal:  Oncogene       Date:  2022-09-16       Impact factor: 8.756

4.  In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates.

Authors:  Mahmoud Saad Abdel-Halim; Momen Askoura; Basem Mansour; Galal Yahya; Amira M El-Ganiny
Journal:  J Antibiot (Tokyo)       Date:  2022-09-27       Impact factor: 3.424

5.  Native Endophytes of Tripterygium wilfordii-Mediated Biotransformation Reduces Toxicity of Celastrol.

Authors:  Ping-Yang Ma; Wei-Ling Geng; Hong-Yan Ji; Bang-Wen Yue; Cheng Liu; Sa Wang; Zhi-Bo Jiang; Jing Chen; Xiu-Li Wu
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

6.  Antimicrobial Activity and Mode of Action of Celastrol, a Nortriterpen Quinone Isolated from Natural Sources.

Authors:  Nayely Padilla-Montaño; Leandro de León Guerra; Laila Moujir
Journal:  Foods       Date:  2021-03-11

7.  Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer.

Authors:  Xiaohu Zeng; Xin Zhu; Qikang Tian; Xiaoke Tan; Ning Sun; Min Yan; Junwei Zhao; Xiangxiang Wu; Ruiqin Li; Zhenqiang Zhang; Huahui Zeng
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulation.

Authors:  Mahmoud Youns; Momen Askoura; Hisham A Abbas; Gouda H Attia; Ahdab N Khayyat; Reham M Goda; Ahmad J Almalki; El-Sayed Khafagy; Wael A H Hegazy
Journal:  Onco Targets Ther       Date:  2021-06-23       Impact factor: 4.147

Review 9.  Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications.

Authors:  Pushkaraj Rajendra Wagh; Preshita Desai; Sunil Prabhu; Jeffrey Wang
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

Review 10.  Multiple Myeloma Inhibitory Activity of Plant Natural Products.

Authors:  Karin Jöhrer; Serhat Sezai Ҫiҫek
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.